Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2017 Mar 7;16(6):1133–1144. doi: 10.1158/1535-7163.MCT-16-0719

Table 1.

FAK protein expression in MDS patient samples by RPPA.

mean SD median min max >norm
(%)
<norm
(%)
=norm
(%)
Obs.
Num
All MDS −0.002 0.857 −0.078 −3.523 4.631 90.7 3.2 6.1 279
All CD34+ 0.055 0.892 −0.052 −3.523 4.631 91.6 2.1 6.3 191
New CD34+ 0.078 0.929 −0.089 −2.236 4.631 91.4 1.7 6.9 116
Rel CD34+ 0.026 0.847 −0.018 −3.523 2.328 91.8 2.7 5.5 73
All SC −0.125 0.767 −0.112 −3.099 1.793 88.6 5.7 5.7 88
New SC −0.116 0.895 −0.057 −3.099 1.793 85.1 8.5 6.4 47
Rel SC −0.136 0.607 −0.148 −2.307 1.292 92.5 2.5 5.0 40
CD34+ Control −1.067 0.209 −0.998 −1.413 −0.734 6.2 6.2 87.5 16
CD133+ −0.739 0.293 −0.737 −1.001 −0.268 60.0 0.0 40.0 5
PBMC 0.497 0.404 0.461 −0.022 1.239 100.0 0.0 0.0 9

The protein level is in log2 scale of arbitrary unit. The normal range of the protein level is defined as 90% inter-percentile of protein level in CD34+ control samples. All MDS: All MDS samples analyzed; All CD34+: all CD34+ MDS samples; New CD34+: CD34+ samples from newly diagnosed MDS patients; Rel CD34+: CD34+ samples from relapsed MDS patients; All SC: all CD34+CD38 MDS samples; New SC: CD34+CD38 samples from newly diagnosed MDS patients; Rel SC: CD34+CD38 samples from relapsed MDS patients; SD: standard deviation; > norm (%): percentage above normal range; < norm (%): percentage below normal range; = norm (%): percentage equal normal range; Obs Num: total observed cases per subgroup; PBMC: PB mononuclear cells.